Study guide

8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

Key Takeaways Explain This Topic AI

Acute abdominal pain requires systematic anatomical quadrant analysis, physical sign interrogation (McBurney's, Rovsing's, Psoas, Obturator, Murphy's, Carnett's), and vigilance for life-threatening vascular catastrophes such as acute mesenteric ischemia ('pain out of proportion to exam') and ruptured abdominal aortic aneurysms.

Acute Pancreatitis is diagnosed via the Atlanta Criteria (≥2 of 3: epigastric pain radiating to back, serum lipase ≥3× ULN, or cross-sectional imaging findings); early management centers on goal-directed isotonic crystalloid resuscitation (Lactated Ringer's preferred) and early oral nutrition within 24 hours rather than prolonged bowel rest.

Upper GI Bleeding (proximal to the ligament of Treitz) presents with hematemesis, 'coffee-ground' emesis, or melena, with an elevated BUN-to-Creatinine ratio (>20–30:1); restrictive PRBC transfusion (target Hb 7–8 g/dL) is standard of care.

USPSTF guidelines recommend routine Colorectal Cancer (CRC) screening in all average-risk adults aged 45 to 75 years; screening modalities include annual FIT/hs-gFOBT, stool DNA-FIT every 3 years, flexible sigmoidoscopy/CT colonography every 5 years, or colonoscopy every 10 years; any positive non-colonoscopy screening test mandates a timely diagnostic colonoscopy.

High-risk individuals with a first-degree relative diagnosed with CRC before age 60 (or ≥2 first-degree relatives at any age) must initiate screening colonoscopy at age 40 or 10 years younger than the earliest affected relative, repeated every 5 years.

Last updated: August 2026

Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

Abdominal pain, gastrointestinal bleeding, and oncologic surveillance represent foundational pillars of adult-gerontology primary and urgent care practice. The AGPCNP must synthesize anatomical principles, provocative physical exam maneuvers, laboratory markers, and advanced imaging modalities to rapidly differentiate self-limiting conditions from surgical emergencies and execute guideline-concordant cancer screening.

1. Quadrant-Based Abdominal Pain Differential Diagnosis & Physical Examination Signs +-----------------------------------------------------------------------------+

  • | QUADRANT-BASED DIFFERENTIAL DIAGNOSIS MATRIX |
  • | |
  • | RIGHT UPPER QUADRANT (RUQ) LEFT UPPER QUADRANT (LUQ) |
  • | - Acute Cholecystitis / Biliary Colic - Splenic Infarction / Rupture / Abscess|
  • | - Ascending Cholangitis - Acute Gastritis / Gastric Ulcer |
  • | - Acute Hepatitis / Liver Abscess - Acute Pancreatitis (Tail) |
  • | - Right Lower Lobe Pneumonia / PE - Left Lower Lobe Pneumonia / PE |
  • | - Fitz-Hugh-Curtis Syndrome (PID) - Splenic Flexure Ischemic Colitis |
  • | |
  • | EPIGASTRIC / RETROPERITONEAL PERIUMBILICAL / MID-ABDOMINAL |
  • | - Peptic Ulcer Disease (GU / DU) - Early Acute Appendicitis |
  • | - Acute Pancreatitis (radiates back)- Small Bowel Obstruction (SBO) |
  • | - Acute Coronary Syndrome (Inf. MI) - Acute Mesenteric Ischemia (SMA) |
  • | - Ruptured Abdominal Aortic Aneurysm- Gastroenteritis / Enteritis |
  • | |
  • | RIGHT LOWER QUADRANT (RLQ) LEFT LOWER QUADRANT (LLQ) |
  • | - Acute Appendicitis (McBurney's) - Acute Sigmoid Diverticulitis |
  • | - Crohn's Disease (Terminal Ileitis)- Ischemic Colitis (Watershed area) |
  • | - Cecal Diverticulitis - Ulcerative Colitis Flare |
  • | - Mesenteric Adenitis - Irritable Bowel Syndrome |
  • | - Right Nephrolithiasis / Pyeloneph - Left Nephrolithiasis / Pyeloneph |
  • | - Gynecologic: Ectopic, Ovarian - Gynecologic: Ectopic, Ovarian |
  • | Torsion, Ruptured Cyst, PID Torsion, Ruptured Cyst, PID |
  • +-----------------------------------------------------------------------------+
  • Classic Physical Examination Signs & Eponyms

Physical Sign / Eponym Examination Technique Clinical Interpretation / Pathology

McBurney's Point Tenderness Palpate deeply at 1/3 the distance from the anterior superior iliac spine (ASIS) to the umbilicus. Acute Appendicitis (maximal anatomical location of inflamed appendix base).

Rovsing's Sign Apply deep palpation to the Left Lower Quadrant (LLQ). Positive if pain is referred to the RLQ (indicates peritoneal irritation in appendicitis).

Psoas Sign Patient in left lateral decubitus position; passively extend the right leg at the hip against resistance. Positive if pain occurs in RLQ (indicates Retrocecal Appendicitis irritating iliopsoas muscle).

Obturator Sign Patient supine; flex right hip and knee to 90°, then passively internally rotate the hip. Positive if pain occurs in hypogastrium/RLQ (indicates Pelvic Appendicitis irritating obturator internus).

Carnett's Sign Identify tender focal point; have patient tense abdominal wall muscles by crossing arms and performing a partial sit-up. - Positive (Pain increases/persists): Abdominal Wall Pathology (e.g., Rectus Sheath Hematoma, nerve entrapment).; - Negative (Pain decreases): Visceral intra-abdominal source.

Cullen's Sign Visual inspection of periumbilical region for superficial bluish-purple ecchymosis. Retroperitoneal Hemorrhage (acute necrotizing pancreatitis, ruptured abdominal aortic aneurysm, ruptured ectopic pregnancy).

Grey Turner's Sign Visual inspection of bilateral flanks for ecchymosis. Severe Retroperitoneal Hemorrhage / Hemorrhagic Pancreatitis.

Kehr's Sign Acute, severe pain referred to the left shoulder tip when patient is in supine position. Diaphragmatic irritation from hemoperitoneum or Splenic Rupture .

2. Acute Pancreatitis: Diagnostics, Severity Stratification & Resuscitation

Revised Atlanta Diagnostic Criteria (Requires ≥ 2 of 3 Criteria) +-----------------------------------------------------------------------------+

  • | ATLANTA CRITERIA FOR ACUTE PANCREATITIS |
  • | |
  • | 1. CLINICAL SYMPTOMS |
  • | - Severe, constant, sharp epigastric pain characteristically radiating |
  • | straight through to the mid-back; improved by leaning forward. |
  • | |
  • | 2. BIOCHEMICAL MARKERS |
  • | - Serum LIPASE or AMYLASE >= 3 TIMES the Upper Limit of Normal (ULN). |
  • | * LIPASE is the preferred laboratory marker (higher sensitivity, |
  • | higher specificity, remains elevated for 7-14 days vs. 3-5 days for |
  • | amylase, unaffected by salivary gland pathology). |
  • | |
  • | 3. CROSS-SECTIONAL IMAGING FINDINGS |
  • | - Contrast-Enhanced CT (CECT), MRI, or Transabdominal Ultrasound |
  • | demonstrating characteristic pancreatic inflammation / peripancreatic|
  • | fluid collections. (Note: CT is NOT required at presentation if |
  • | pain + lipase >= 3x ULN are already present!). |
  • +-----------------------------------------------------------------------------+
  • Etiologies of Acute Pancreatitis: "I GET SMASHED"
  • I: Idiopathic
  • G: Gallstones (Biliary) (40% to 50% of all cases — most common!)
  • E: Ethanol (Alcohol) (30% to 35% of all cases — second most common!)
  • T: Trauma (blunt abdominal trauma)
  • S: Steroids
  • M: Mumps and other viral infections (Coxsackievirus, CMV)
  • A: Autoimmune (Type 1/Type 2 IgG4-related autoimmune pancreatitis)
  • S: Scorpion stings
  • H: Hypertriglyceridemia (fasting serum triglycerides > 1,000 mg/dL) & Hypercalcemia
  • E: ERCP (post-procedural mechanical cannulation injury)
  • D: Drugs (Azathioprine, 6-MP, GLP-1 RAs, DDP-4i, Didanosine, Thiazides, Furosemide, Valproate, Sulfonamides)
  • Evidence-Based Resuscitation & Clinical Management

Early Fluid Resuscitation: Goal-directed isotonic crystalloid resuscitation ( Lactated Ringer's solution preferred over Normal Saline; reduces systemic inflammatory response syndrome [SIRS] and hyperchloremic metabolic acidosis). Administer at 200–500 mL/hr (or 5–10 mL/kg/hr) for the first 12–24 hours, adjusting for urine output (> 0.5 mL/kg/hr), hematocrit, and BUN reduction.

Monitoring BUN & Hematocrit: An elevated BUN > 20 mg/dL or rising BUN during hospitalization is the single strongest independent predictor of hemoconcentration, pancreatic necrosis, and inpatient mortality.

Nutrition (Early Oral Feeding): Abandon prolonged "NPO / bowel rest." In mild pancreatitis, initiate early oral feeding with a low-fat solid or liquid diet within 24 hours as soon as abdominal pain and nausea improve. Early enteral nutrition maintains the mucosal gut barrier and prevents bacterial translocation.

Prophylactic Antibiotics: Routine prophylactic intravenous antibiotics are NOT recommended in acute pancreatitis (even in sterile necrotizing pancreatitis), as they do not reduce mortality and select for resistant fungal infections.

Gallstone Pancreatitis: Schedule cholecystectomy during the index admission prior to discharge to prevent fatal recurrent biliary pancreatitis.

3. Bowel Obstruction & Mesenteric Vascular Emergencies +-----------------------------------------------------------------------------+

  • | ACUTE ABDOMINAL VASCULAR & LUMINAL EMERGENCIES |
  • | |
  • | CONDITION HALLMARK CLINICAL SIGNS DIAGNOSTIC & RX PLAN |
  • | ----------------------------------------------------------------------- |
  • | Small Bowel Colicky periumbilical pain, Abdominal CT: Dilated |
  • | Obstruction (SBO) bilious vomiting, obstipation, loops >3cm, air-fluid |
  • | hyperactive high-pitched levels, transition pt. |
  • | "tinkling" bowel sounds. Rx: NG decompression, |
  • | #1 Cause: ADHESIONS from prior IV fluids, surgery |
  • | abdominopelvic surgery (60-70%) consult. |
  • | |
  • | Acute Mesenteric "PAIN OUT OF PROPORTION TO DIAGNOSTIC GOLD-STD: |
  • | Ischemia (SMA PHYSICAL EXAM" (Severe CT ANGIOGRAPHY (CTA) of|
  • | Embolism / Thromb) agonizing abdominal pain with Abdomen & Pelvis. |
  • | minimal initial tenderness!). Elevated LACTIC ACID |
  • | History of AFib, CAD, or PVD. indicates bowel necrosis|
  • | Postprandial "intestinal Rx: Urgent surgical / |
  • | angina" and food fear. endovascular revasc. |
  • | |
  • | Colonic Ischemia Transient hypoperfusion to Abdominal CT: segmental|
  • | (Ischemic Colitis) "WATERSHED AREAS" (Splenic thickening. Confirm via|
  • | flexure = Griffiths' point; COLONOSCOPY (pale, |
  • | Rectosigmoid = Sudeck's point). cyanotic mucosa). |
  • | Elderly post-op/hypotension. Rx: Supportive, IV |
  • | Crampy LLQ pain + MILD fluids, optimize |
  • | HEMATOCHEZIA (bloody stool). cardiac output. |
  • +-----------------------------------------------------------------------------+

4. Gastrointestinal Bleeding: Upper vs. Lower GI Bleed Differentiation +-----------------------------------------------------------------------------+

  • | UPPER vs. LOWER GASTROINTESTINAL BLEEDING |
  • | |
  • | FEATURE UPPER GI BLEED (UGIB) LOWER GI BLEED (LGIB) |
  • | ----------------------------------------------------------------------- |
  • | Anatomical Landmark PROXIMAL to Ligament of DISTAL to Ligament of |
  • | Treitz (Duodenojejunal) Treitz |
  • | Most Common Etiologies - Peptic Ulcer Disease - Diverticular Bleed |
  • | - Gastroesophageal Varices - Angiodysplasia |
  • | - Mallory-Weiss Tears - Ischemic Colitis |
  • | - Gastric Malignancy - Polyps / Colorectal Ca|
  • | - Dieulafoy Lesion - Hemorrhoids / IBD |
  • | Clinical Presentation - HEMATEMESIS (bright red - HEMATOCHEZIA (bright |
  • | or "coffee-ground") red / maroon per |
  • | - MELENA (black, tarry, rectum) |
  • | foul-smelling stool) - Melena rare (only if |
  • | - Massive rapid UGIB can slow right colonic) |
  • | present as hematochezia! |
  • | BUN-to-Creatinine Ratio ELEVATED (> 20 - 30 : 1) NORMAL (< 15 - 20 : 1) |
  • | (Digestion and absorption |
  • | of luminal blood proteins) |
  • | Initial Diagnostic Test ESOPHAGOGASTRODUODENOSCOPY COLONOSCOPY |
  • | (EGD within 24 hours) (after bowel prep) |
  • +-----------------------------------------------------------------------------+
  • Clinical Stabilization & Transfusion Protocols

Hemodynamic Resuscitation: Place two large-bore peripheral IV lines (16- or 18-gauge) or central venous access; immediately type and crossmatch blood.

Restrictive Transfusion Strategy: The landmark TRICC and Villanueva trials demonstrated that a restrictive PRBC transfusion strategy (transfuse when Hemoglobin < 7.0 g/dL to maintain a target of 7.0–8.0 g/dL) significantly reduces rebleeding rates, fluid overload, and all-cause mortality compared to liberal transfusion (< 9.0 g/dL). Exception: Patients with concurrent acute coronary syndrome or active symptomatic ischemic heart disease maintain a transfusion threshold of Hb < 8.0 g/dL.

Medical Therapy for UGIB: High-dose IV Proton Pump Inhibitor ( Pantoprazole or Esomeprazole 80 mg IV bolus followed by 8 mg/hr continuous infusion or 40 mg IV BID) to maintain intragastric pH > 6.0, which stabilizes clot formation. If cirrhosis/variceal bleeding is suspected: add IV Octreotide (50 mcg bolus then 50 mcg/hr infusion) and IV Ceftriaxone (1g daily) .

5. Colorectal Cancer (CRC) Screening Guidelines

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related mortality in the United States. Nearly all CRCs arise from adenomatous polyps or sessile serrated lesions over a 10- to 15-year neoplastic cascade.

USPSTF & Multi-Society Task Force Guidelines for Average-Risk Adults

In 2021, the United States Preventive Services Task Force (USPSTF) lowered the recommended starting age for average-risk colorectal cancer screening from 50 to 45 years due to the rising incidence of early-onset colorectal carcinoma. +-----------------------------------------------------------------------------+

  • | USPSTF CRC SCREENING AGE THRESHOLDS |
  • | |
  • | AGE GROUP SCREENING RECOMMENDATION |
  • | ----------------------------------------------------------------------- |
  • | Ages 45 to 75 years UNIVERSAL ROUTINE SCREENING (Grade A/B). |
  • | Strong net clinical benefit for all adults. |
  • | |
  • | Ages 76 to 85 years SELECTIVE / INDIVIDUALIZED DECISION-MAKING (Grade C)|
  • | Based on overall health, comorbid disease, prior |
  • | screening history, and life expectancy > 10 years.|
  • | |
  • | Age > 85 years DISCONTINUE ROUTINE SCREENING (Grade D). |
  • | Risks of screening/colonoscopy outweigh benefit. |
  • +-----------------------------------------------------------------------------+
  • Comparison of Screening Modalities & Intervals

Screening Modality Category Recommended Interval Advantages & Clinical Rules

Colonoscopy Direct Visualization Every 10 years Gold standard. Evaluates entire colon, allows immediate therapeutic polypectomy. Requires bowel prep and sedation.

Fecal Immunochemical Test (FIT) Stool-Based Biomarker Annually High sensitivity for human globin; specific for lower GI bleeding. No dietary restrictions required.

Stool DNA-FIT (sDNA-FIT / Cologuard) Stool-Based Biomarker Every 3 years Combines FIT with molecular methylation/mutation DNA markers ( KRAS , BMP3 , NDRG4 ). Higher sensitivity for adenomas than FIT alone, but higher false-positive rate.

High-Sensitivity Guaiac (hs-gFOBT) Stool-Based Biomarker Annually Detects heme peroxidase activity. Requires strict dietary restrictions (avoid red meat, vitamin C, NSAIDs for 3 days prior).

Flexible Sigmoidoscopy Direct Visualization Every 5 years (or every 10 yrs + annual FIT) Visualizes distal colon only (splenic flexure down). No sedation required, but misses proximal right-sided colonic neoplasia.

CT Colonography (Virtual Colonoscopy) Radiographic Imaging Every 5 years Evaluates entire colon without sedation. Requires bowel prep. Radiation exposure; extracolonic incidental findings.

Important

The Universal Screening Rule: Any positive non-colonoscopy screening test (such as a positive annual FIT, positive sDNA-FIT/Cologuard, or polyps identified on CT colonography / flexible sigmoidoscopy) REQUIRES A TIMELY DIAGNOSTIC FOLLOW-UP COLONOSCOPY . The primary care provider must counsel patients that stool tests are screening tools, not diagnostic endpoints.

High-Risk Colorectal Cancer Screening Protocols +-----------------------------------------------------------------------------+

  • | HIGH-RISK COLORECTAL CANCER ALGORITHMS |
  • | |
  • | CLINICAL RISK CATEGORY SCREENING PROTOCOL |
  • | ----------------------------------------------------------------------- |
  • | 1. Single 1st-Degree Relative with Begin Colonoscopy at AGE 40 |
  • | CRC or Advanced Adenoma at OR 10 YEARS YOUNGER than the age |
  • | AGE < 60 YEARS; OR of diagnosis in the youngest |
  • | Two or more 1st-degree relatives affected relative (whichever comes |
  • | diagnosed at ANY age first!). |
  • | REPEAT EVERY 5 YEARS. |
  • | |
  • | 2. Single 1st-Degree Relative with Begin Colonoscopy at AGE 40. |
  • | CRC or Advanced Adenoma at REPEAT EVERY 5 to 10 YEARS. |
  • | AGE >= 60 YEARS |
  • | |
  • | 3. Lynch Syndrome (HNPCC: MLH1, Begin Colonoscopy at AGE 20 to 25 |
  • | MSH2, MSH6, PMS2 mutations) (or 2-5 yrs prior to earliest dx). |
  • | REPEAT EVERY 1 to 2 YEARS. |
  • | |
  • | 4. Familial Adenomatous Polyposis Begin Annual Flexible Sigmoidoscopy|
  • | (FAP: APC gene mutation, or Colonoscopy at AGE 10 to 12. |
  • | thousands of polyps) Mandates prophylactic colectomy. |
  • +-----------------------------------------------------------------------------+